Trials / Unknown
UnknownNCT03727763
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT): A Single-arm Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Changzheng Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vemurafenib | 960mg po bid |
| DRUG | Cetuximab | 500mg/m2 iv gtt (14 days per course) |
Timeline
- Start date
- 2018-10-08
- Primary completion
- 2021-12-01
- Completion
- 2022-12-31
- First posted
- 2018-11-01
- Last updated
- 2021-08-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03727763. Inclusion in this directory is not an endorsement.